2022
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchMeSH KeywordsBlood TransfusionGraft vs Host DiseaseHumansLeukocyte CountLeukocytesTransfusion ReactionConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2010
In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system
Snyder EL, Whitley P, Kingsbury T, Miripol J, Tormey CA. In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system. Transfusion 2010, 50: 2145-2151. PMID: 20497514, DOI: 10.1111/j.1537-2995.2010.02701.x.Peer-Reviewed Original ResearchConceptsRed blood cellsWhite blood cellsAutologous plateletsTransfusion productsBlood cellsAdverse clinical sequelaeCPD plasmaProduction of plateletsResidual white blood cellsClinical sequelaeDrug Administration requirementsHospital useVivo efficacyLeukoreduction filtersBlood centersStudy designVivo evaluationLR productsVivo characteristicsPlateletsRBC recoveryAdministration requirementsVitroSurvival ratioFDA guidelines